Seeking regulatory (IVDR/MDR) & HTA partners to build complementary exploitation teams

AxioTechBio contributes hands-on commercial exploitation, go-to-market and public procurement expertise (France, Spain) to Horizon Europe Cluster 1 Health 2027 consortia, together with access to a network of European omics and diagnostics SMEs.

Topics such as IND-02 (point-of-care diagnostics) and TOOL-01 (AI predictive biomarkers) require both an exploitation plan and a regulatory strategy (IVDR/MDR, biomarker qualification) and, in some cases, HTA considerations. We are looking for partners from across Europe with proven regulatory and/or HTA expertise to approach coordinators jointly with a complete exploitation and market uptake package.

Looking for:

– Regulatory affairs SMEs and consultancies (IVDR/MDR, notified body interaction, performance evaluation, AI Act)

– HTA and health economics experts

– Organisations interested in co-leading exploitation and uptake tasks in Health 2027 proposals